Adding cofrogliptin or linagliptin to insulin for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests two oral diabetes pills, cofrogliptin and linagliptin, when added to your current insulin treatment. The goal is to see if these pills help improve blood sugar control without causing extra side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 2 diabetes, not type 1.
- Your recent blood sugar test (HbA1c) is between 7% and 9%, and your fasting blood sugar is 11 mmol/L or lower.
- You have been on a stable insulin regimen (basal, premixed, or IDegAsp) for at least 12 weeks, with or without metformin, SGLT2 inhibitors, or alpha-glucosidase inhibitors (up to 3 total diabetes pills).
- You are willing to start or have already started cofrogliptin or linagliptin within 2 weeks before or after signing the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This study compares two oral diabetes medicines, cofrogliptin and acarbose, to see which works better and has fewer side effects in people who are new to diabetes medication. If you qualify, you would take one of these pills daily, and the study will help you manage your blood sugar.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
This trial tests a new combination pill (henagliflozin and metformin) compared to metformin alone in people recently diagnosed with type 2 diabetes. The goal is to see which treatment works better and is safer.
This study tests a new once-every-2-weeks pill (cofrogliptin) added to your current diabetes medications (metformin and dapagliflozin) compared to a daily pill (linagliptin). It may help improve blood sugar control with fewer daily pills.
This study tests a new medication called LID104 added to your usual metformin to see if it improves blood sugar control in people with type 2 diabetes. If you qualify, you'll get the study drug or a placebo (inactive pill) to compare how well it works.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.